Beyond Air (XAIR) to Release Earnings on Monday

Beyond Air (NASDAQ:XAIR) is set to post its quarterly earnings results after the market closes on Monday, November 11th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Beyond Air (NASDAQ:XAIR) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.12. Beyond Air had a negative return on equity of 240.15% and a negative net margin of 3,272.46%. The business had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $0.72 million. During the same period in the prior year, the firm earned ($0.45) EPS. On average, analysts expect Beyond Air to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Beyond Air Trading Down 14.0 %

XAIR stock opened at $0.49 on Monday. The firm has a fifty day moving average price of $0.40 and a 200 day moving average price of $0.72. Beyond Air has a fifty-two week low of $0.30 and a fifty-two week high of $2.61. The firm has a market cap of $23.13 million, a PE ratio of -0.30 and a beta of -0.18. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.42 and a current ratio of 2.63.

Insider Buying and Selling

In other news, CEO Steven A. Lisi acquired 1,476,626 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was acquired at an average price of $0.50 per share, with a total value of $738,313.00. Following the completion of the purchase, the chief executive officer now directly owns 3,249,411 shares in the company, valued at approximately $1,624,705.50. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Beyond Air news, CEO Steven A. Lisi acquired 1,476,626 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were bought at an average price of $0.50 per share, with a total value of $738,313.00. Following the transaction, the chief executive officer now directly owns 3,249,411 shares of the company’s stock, valued at $1,624,705.50. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Steven A. Lisi bought 100,000 shares of the stock in a transaction dated Wednesday, August 14th. The shares were bought at an average cost of $0.39 per share, with a total value of $39,000.00. Following the completion of the purchase, the chief executive officer now directly owns 1,722,785 shares of the company’s stock, valued at approximately $671,886.15. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 1,615,892 shares of company stock valued at $793,019. Company insiders own 19.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on XAIR. Roth Capital upgraded shares of Beyond Air to a “strong-buy” rating in a report on Friday, August 16th. Roth Mkm reissued a “buy” rating and set a $2.00 price objective on shares of Beyond Air in a research note on Friday, August 16th. Finally, Piper Sandler decreased their price objective on Beyond Air from $3.50 to $1.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $3.67.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.